NCT04274023 (ACCeSs) is a Phase 2 clinical trial of TSR-042 in Sarcoma, Clear Cell, sponsored by Italian Sarcoma Group.

Who is sponsoring NCT04274023?

NCT04274023 is sponsored by Italian Sarcoma Group.

What drugs are being tested in NCT04274023?

Interventions in NCT04274023: TSR-042.

What condition does NCT04274023 study?

NCT04274023 studies Sarcoma, Clear Cell.

Is NCT04274023 still recruiting?

NCT04274023 is currently terminated. Last updated 1 February 2024.

Last reviewed 2024-02-01 · How we verify

NCT04274023: ACCeSs

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study on TSR-042 in Advanced Clear Cell Sarcoma

Terminated Phase 2 Last updated 1 February 2024

What this trial tests

Phase 2 trial testing TSR-042 in Sarcoma, Clear Cell in 3 participants. Terminated before completion.

Timeline

29 January 2024

Primary endpoint
29 January 2024

29 January 2024

Quick facts

Lead sponsor	Italian Sarcoma Group
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	29 January 2024
Primary completion	29 January 2024
Estimated completion	29 January 2024
Sites	1 location across Italy

Drugs / interventions tested

TSR-042 — full drug profile →

Conditions studied

Sarcoma, Clear Cell — all drugs for Sarcoma, Clear Cell →

Sponsor

Italian Sarcoma Group — full company profile →

Who can join

18 and older, any sex, with Sarcoma, Clear Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase II,single arm study designed to explore the activity of TSR-042, an immunotherapy agent, in patients with a diagnosis of advanced or metastatic clear cell sarcoma (CCS).

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions.
Pansy K, Uhl B, Krstic J, Szmyra M, et al · · 2021 · cited 87× · PMID 34948104 · DOI 10.3390/ijms222413311
Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
Roulleaux Dugage M, Nassif EF, Italiano A, Bahleda R. · · 2021 · cited 73× · PMID 34925348 · DOI 10.3389/fimmu.2021.775761
Systemic treatment of advanced clear cell sarcoma: results from a retrospective international series from the World Sarcoma Network.
Smrke A, Frezza AM, Giani C, Somaiah N, et al · · 2022 · cited 19× · PMID 35717681 · DOI 10.1016/j.esmoop.2022.100522
Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer.
Alkholifi FK, Alsaffar RM. · · 2022 · cited 17× · PMID 36363529 · DOI 10.3390/medicina58111572
Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas.
Kerrison WGJ, Lee ATJ, Thway K, Jones RL, et al · · 2022 · cited 16× · PMID 35327375 · DOI 10.3390/biomedicines10030573

Verify or expand the search:

Other trials of TSR-042

Trials testing the same drug.

NCT03955978 — TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer · Phase 1 · active not recruiting
NCT03574779 — A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer · Phase 2 · completed
NCT03307785 — Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 · Phase 1 · completed
NCT02817633 — A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) · Phase 1 · active not recruiting

Other Italian Sarcoma Group trials

Trials by the same sponsor.

NCT07265661 — Surgical Timing After Preoperative Hypofractionated Radiotherapy for Localized Extremity and Trunk Soft Tissue Sarcoma · NA · not yet recruiting
NCT07328425 — Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS · Phase 2 · recruiting
NCT06375941 — Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars · recruiting
NCT04383119 — Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma · Phase 2 · recruiting
NCT04305548 — Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04274023 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Italian Sarcoma Group
Last refreshed: 1 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04274023.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing